HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-01-2019, 05:21 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Lightbulb FDA approves Subcutaneous Herceptin for her2+ Breast Cancer

Subcutaneous Herceptin OK'd for Breast Cancer
Study found 86% of patients preferred it to IV formulation



by Ian Ingram, Deputy Managing Editor, MedPage Today
February 28, 2019

WASHINGTON -- The FDA approved a subcutaneous version of trastuzumab (Herceptin) for treating HER2-positive breast cancer on Thursday.

Two randomized trials confirmed the safety and efficacy of the new formulation, which combines the anti-HER2 targeted agent with hyaluronidase, an endoglycosidase, and will be branded Herceptin Hylecta.

In the HannaH trial, 596 operable, HER2-positive breast cancer patients with locally advanced or inflammatory disease were randomized to 8 cycles of chemotherapy plus either subcutaneous or intravenous trastuzumab. Following surgery, they received another 10 cycles of their respective trastuzumab therapy.

The study met both primary endpoints, demonstrating that subcutaneous trastuzumab's pharmacokinetics and rates of pathological complete response (pCR) were noninferior to standard IV therapy. Rates of pCR were 45.4% in the subcutaneous arm compared with 40.7% in the IV arm (4.7% difference, 95% CI -4.0% to 13.4%).

Adverse events (AEs) between the two formulations were generally similar in this study, but serious AEs occurred with more frequency in the subcutaneous group (21.0% vs 12.0%), driven mostly by increased rates of infections and infestations (8.1% vs 4.4%).

A second study, SafeHER, was a prospective, multinational, open-label trial that confirmed the safety and tolerability of subcutaneous trastuzumab in 1,864 HER2-positive breast cancer patients treated every 3 weeks for 18 cycles.

The most common AEs (≥10%) were arthralgia, cough, diarrhea, edema, fatigue, flushing, headache, injection site reactions, myalgia, nausea, pain in the extremities, pyrexia, rash, and upper respiratory tract infections.

A third study, PrefHER, examined patient preference. In it, 240 patients were randomized to subcutaneous trastuzumab followed by the IV formulation, or vice versa. Following treatment, 86% stated that they preferred the subcutaneous version, 13% the IV version, and 1% had no preference. As the subcutaneous formulation takes about 2 to 5 minutes to administer, time savings was the most common reason for preference over the IV version, which can take from 30 to 90 minutes. Those preferring the IV version cited injection site reactions as their reason.

The recommended dose of the new treatment is 600 mg trastuzumab and 10,000 units hyaluronidase administered subcutaneously every 3 weeks.
Lani is offline   Reply With Quote
Old 03-09-2019, 06:06 PM   #2
StephN
Senior Member
 
StephN's Avatar
 
Join Date: Nov 2004
Location: Misty woods of WA State
Posts: 4,128
Wink Re: FDA approves Subcutaneous Herceptin for her2+ Breast Cancer

Thank you so much for this, Learned Lani!

I would like more information as to the exact procedure, cost and wide market date expectations. Can you post the company website or any other such info?

Again, thanks a million for keeping this site informed.
__________________
"When I hear music, I fear no danger. I am invulnerable. I see no foe. I am related to the earliest times, and to the latest." H.D. Thoreau
Live in the moment.

MY STORY SO FAR ~~~~
Found suspicious lump 9/2000
Lumpectomy, then node dissection and port placement
Stage IIB, 8 pos nodes of 18, Grade 3, ER & PR -
Adriamycin 12 weekly, taxotere 4 rounds
36 rads - very little burning
3 mos after rads liver full of tumors, Stage IV Jan 2002, one spot on sternum
Weekly Taxol, Navelbine, Herceptin for 27 rounds to NED!
2003 & 2004 no active disease - 3 weekly Herceptin + Zometa
Jan 2005 two mets to brain - Gamma Knife on Jan 18
All clear until treated cerebellum spot showing activity on Jan 2006 brain MRI & brain PET
Brain surgery on Feb 9, 2006 - no cancer, 100% radiation necrosis - tumor was still dying
Continue as NED while on Herceptin & quarterly Zometa
Fall-2006 - off Zometa - watching one small brain spot (scar?)
2007 - spot/scar in brain stable - finished anticoagulation therapy for clot along my port-a-catheter - 3 angioplasties to unblock vena cava
2008 - Brain and body still NED! Port removed and scans in Dec.
Dec 2008 - stop Herceptin - Vaccine Trial at U of W begun in Oct. of 2011
STILL NED everywhere in Feb 2014 - on wing & prayer
7/14 - Started twice yearly Zometa for my bones
Jan. 2015 checkup still shows NED
2015 Neuropathy in feet - otherwise all OK - still NED.
Same news for 2016 and all of 2017.
Nov of 2017 - had small skin cancer removed from my face. Will have Zometa end of Jan. 2018.
StephN is offline   Reply With Quote
Old 03-24-2019, 05:35 PM   #3
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Re: FDA approves Subcutaneous Herceptin for her2+ Breast Cancer

Given subcutaneously by nurse. Average visit 5 minutes. No loading dose required. No modification of dose for body weight required. Given every 3 weeks. Not to be administered by patient themselves. Cost savings comes from less facility, nurse time.

Popular in rest of world.

Available in April, perhaps as soon as April 1. Whether insurance will reimburse /when as yet undetermined. Genentech urged providers to utilize their access
program in the interim
Lani is offline   Reply With Quote
Old 03-28-2019, 10:27 PM   #4
StephN
Senior Member
 
StephN's Avatar
 
Join Date: Nov 2004
Location: Misty woods of WA State
Posts: 4,128
Wink Re: FDA approves Subcutaneous Herceptin for her2+ Breast Cancer

Thank you. If I ever need Herceptin again, this is a great alternative since my port cath damaged the vein it was in for 9 years. (I now have a rather large stent in that damaged area.) A boon for many other who may not need a port.
__________________
"When I hear music, I fear no danger. I am invulnerable. I see no foe. I am related to the earliest times, and to the latest." H.D. Thoreau
Live in the moment.

MY STORY SO FAR ~~~~
Found suspicious lump 9/2000
Lumpectomy, then node dissection and port placement
Stage IIB, 8 pos nodes of 18, Grade 3, ER & PR -
Adriamycin 12 weekly, taxotere 4 rounds
36 rads - very little burning
3 mos after rads liver full of tumors, Stage IV Jan 2002, one spot on sternum
Weekly Taxol, Navelbine, Herceptin for 27 rounds to NED!
2003 & 2004 no active disease - 3 weekly Herceptin + Zometa
Jan 2005 two mets to brain - Gamma Knife on Jan 18
All clear until treated cerebellum spot showing activity on Jan 2006 brain MRI & brain PET
Brain surgery on Feb 9, 2006 - no cancer, 100% radiation necrosis - tumor was still dying
Continue as NED while on Herceptin & quarterly Zometa
Fall-2006 - off Zometa - watching one small brain spot (scar?)
2007 - spot/scar in brain stable - finished anticoagulation therapy for clot along my port-a-catheter - 3 angioplasties to unblock vena cava
2008 - Brain and body still NED! Port removed and scans in Dec.
Dec 2008 - stop Herceptin - Vaccine Trial at U of W begun in Oct. of 2011
STILL NED everywhere in Feb 2014 - on wing & prayer
7/14 - Started twice yearly Zometa for my bones
Jan. 2015 checkup still shows NED
2015 Neuropathy in feet - otherwise all OK - still NED.
Same news for 2016 and all of 2017.
Nov of 2017 - had small skin cancer removed from my face. Will have Zometa end of Jan. 2018.
StephN is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 05:25 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter